Recent News and Updates
WDA designates newest Wilson Disease Center of Excellence at University of California, Davis
Read more: https://health.ucdavis.edu/news/headlines/uc-davis-health-designated-wilson-disease-center-of-excellence/2024/09
Vivet Therapeutics Wilson Disease Update April 2024
Dear members of the Wilson disease community, We are pleased to update you on the progress of GATEWAY, the first gene therapy clinical study evaluating the effects of Vivet’s investigational therapy VTX-801, which is [...]
Ultragenyx Wilson Disease Update April 2024
As Ultragenyx continues to advance its research for Wilson disease, please find a status update on the CYPRUS2+ study. The CYPRUS2+ study is designed with three stages. We are currently in Stage 1 where [...]
One Step Closer to a Newborn Screening Test for Wilson Disease
Key Proteo Submits De Novo Application to FDA for its First Newborn Screening Kit Potential to be the first IVD for the screening of Wilson Disease, Wiskott-Aldrich Syndrome, X-linked Agammaglobulinemia and Adenosine Deaminase Deficiency [...]
Ultragenyx Wilson Disease Gene Therapy Trial Update for WDA
As requested, we are providing an update on Stage 1 of our Cyprus2+ study, assessing safety and efficacy of UX701, an investigational gene therapy for the treatment of Wilson disease. The status update below [...]
Vivet Therapeutics’ Wilson Disease Gene Therapy Clinical Trial Update
On behalf of the Vivet Therapeutics Wilson disease study team, we are happy to share updates about the ongoing and enrolling GATEWAY clinical trial.GATEWAY is an international gene therapy clinical trial for people living with [...]